People | June 13, 2025
Sun Pharma appoints Kirti Ganorkar as the Managing Director
Dilip Shanghvi to continue as the Executive Chairman of the Board
Dilip Shanghvi to continue as the Executive Chairman of the Board
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi (Sovateltide)
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies
Subscribe To Our Newsletter & Stay Updated
